Head & Neck Cancers

Ezra E. W. Cohen, MD, has focused on the role of EGFR inhibitors in much of his research into head and neck cancers.

Dr. Ezra Cohen from the University of Chicago Discusses Head and Neck Cancer Pathways

If IKK kinase, a group of inhibitory proteins, activity is not regulated properly, tumors in the body have the ability to migrate and proliferate.

Ezra E. W. Cohen, MD, is a physician and translational researcher at the University of Chicago Medical Center, that focuses on epidermal growth factor receptor (EGFR) inhibitors.

Cetuximab (Erbitux) was approved by the FDA for treating patients with late-stage head and neck cancer in combination with chemotherapy.

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Meeting.

Dr. Barbara Burtness from Fox Chase Cancer Center on the Head and Neck Symposium Design

Dr. Barbara Burtness from Fox Chase Cancer Center Discusses the Upcoming Head and Neck Cancer Symposium

Panitumumab + chemo improves OS and PFS in patients with metastatic carcinoma of the head and neck that were negative for HPV.

The 2 upcoming conferences include the 7th Annual Multidisciplinary Symposium on Head and Neck Cancer and the School of Breast Oncology.

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Patients with locally advanced head and neck cancer gained no survival benefit with the addition of cetuximab to chemoradiation.

Previously unknown genetic methylation patterns and new mutations for squamous cell carcinoma of the head and neck discovered.

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Patients with basal cell carcinoma had an eightfold decrease in lesion area when treated with GDC-0449

Primary cancers of the lung, esophagus, and pancreas-all of which have a poor prognosis-account for >35% of all cancer deaths in the United States annually

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

Singer and songwriter Charlie Lustman has become an inspirational voice for the over 12 million cancer survivors living in the United States

The FDA has approved vandetanib for the treatment of unresectable, late-stage, metastatic medullary thyroid cancer

It has been more than half a century since radiation treatment was mistakenly deemed necessary to help infants with enlarged thymus glands avoid the risk of status lymphaticus and suffocation

New data suggest that office-based injection laryngoplasty (IL) appears to be a safe and effective treatment for laryngeal dysfunction in cancer patients.

New findings indicate that prereferral care does not conform to clinical practice guidelines in nearly half of patients with head and neck cancer who are referred to a tertiary care center with persistent or recurrent disease, new findings indicate.

Useful Online Resources and Clinical Trials for Head and Neck Cancers